P&T Cmte. Anonymity Reduces Bias, Caremark Says; A Model For Medicare?
Executive Summary
Caremark relies on anonymity as one means to reduce bias in the pharmacy & therapeutic committee review process
You may also be interested in...
Formularies Would Be Authorized But Restricted Under Senate Medicare Bill
The Senate Finance Medicare drug coverage bill includes language dictating that beneficiaries cannot be forced to pay a higher copay for a non-formulary product if it is determined to be medically necessary
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials